Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Dainippon Sees Success In Phase III Trials For Schizophrenia Drug

This article was originally published in PharmAsia News

Executive Summary

Dainippon Sumitomo Pharma of Japan reported Phase III success with its lurasidone drug to treat schizophrenia. The company said that as a result, it plans to apply to the U.S. FDA early next year for approval. The drug is part of the atypical antipsychotics class of drug that works by blocking brain serotonin receptors. The final-stage trial was conducted on patients who had schizophrenia for an average of 13 years and had been hospitalized recently. (Click here for more

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts